NPPB and hydrops fetalis: Lastly, in the ASCEND trial [49], adding 48 to 72 h of follow-up sST2 to the ASCEND-HF risk model, plus follow-up NT-proBNP, correctly reclassified 15.6% of subjects for the 180-day death endpoint.